PMC report: FDA addressed rare diseases, expanded cancer treatment and targeted therapies in 2019

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A Feb. 21 Personalized Medicine Coalition report says 12 personalized treatments and seven diagnostics approved or cleared by FDA in 2019 will improve patient care and address root causes of rare diseases, expand treatment for cancer patients, and target therapies to people who respond.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login